Blindness News and Research

RSS

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

1 Oct 2015

New research sheds light on how retina sets its own biological rhythm using neuropsin

Researchers at Johns Hopkins and the University of Washington report new research that sheds light on how the retina sets its own biological rhythm using a novel light-sensitive pigment, called neuropsin, found in nerve cells at the back of the eye.

1 Oct 2015

Researchers receive NIH grants to find genomic regions containing variants that affect disease risk

Six new grants from the National Institutes of Health will support researchers to develop new computational approaches for searching among millions of genomic variants to find those that make a difference in disease susceptibility or in other traits.

23 Sep 2015

University of Alberta researchers discover diabetes 'dimmer' switch

Patrick MacDonald has dedicated much of his life to diabetes research. It's a job he knows is far too large and complex for any one person, but with his latest publication, he knows his work is playing a part.

23 Sep 2015

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven’s Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

18 Sep 2015

UK’s GPs, optometrists confirm link between smoking and loss of vision

Smokey eyes are regarded as sexy, sultry and stunning. But nothing could be further from the truth, according to new research unveiled this National Eye Health Week.

18 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

World Scientific's latest book to be launched on Stem Cell Awareness Day

While the world knows the $3 billion California Institute for Regenerative Medicine sprang from the citizen's initiative, Proposition 71, few people know the struggle required, nor what happened after California said "Yes!"

16 Sep 2015

AMD Alliance hosts webinar to promote awareness and knowledge about macular disease

14 – 20 September marks global AMD Awareness Week 2015. Age related macular degeneration (AMD) is a progressive eye disease which is the leading cause of blindness in over 50s globally.

16 Sep 2015

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.

15 Sep 2015

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Scientists at the University of California, San Diego School of Medicine have elucidated a genetic interaction that may prove key to the development and progression of glaucoma, a blinding neurodegenerative disease that affects tens of millions of people worldwide and is a leading cause of irreversible blindness.

11 Sep 2015

Envision inaugurates 10th Annual Conference, honors outstanding achievements in low vision rehabilitation

Envision, the Wichita, Kan.-based not-for-profit organization that supports those who are blind and visually impaired, officially opened its 10th Annual Conference at The Grand Hyatt in downtown Denver this morning with a session honoring outstanding commitment to improving the quality of life of those who are blind and visually impaired and keynote addresses from two individuals representing the great athletic accomplishments those with vision loss can achieve.

11 Sep 2015

IRIDEX launches novel intra-ocular pressure monitoring device

IRIDEX Corporation today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator of the tonometer.

8 Sep 2015

Kilimanjaro Project receives 2015 António Champalimaud Vision Award

The 2015 António Champalimaud Vision Award is given to three institutions that have developed a unique collaborative project to achieve the common goal of fighting blindness and poverty in Africa.

7 Sep 2015

New findings hold promising implications for blindness caused by limbal stem cell deficiency

Researchers at the University of Oslo have made discoveries that can have great consequences for the treatment of blindness caused by so-called limbal stem cell deficiency.

4 Sep 2015

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan plc, a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

4 Sep 2015

Mitochondrial Pyruvate Carrier could potentially be a new drug target to treat diabetes

High blood sugar is a defining characteristic of Type 2 diabetes and the cause of many of the condition's complications, including kidney failure, heart disease, and blindness. Most diabetes medications aim to maintain normal blood sugar (glucose) levels and prevent high blood sugar by controlling insulin.

3 Sep 2015

Central visual field loss may delay driver's ability to detect pedestrians in timely manner

Vision researchers in Boston have published the second paper of a study designed to determine if a driver who suffers from loss of central vision is able to detect pedestrians in a timely manner when driving.

3 Sep 2015

Annual diabetic retinopathy screening for children with type 1 diabetes should begin at later age, study says

A new study has found that the occurrence of advanced forms of a diabetic eye disease remains low among children living with diabetes, regardless of how long they have had the disease or their ability to keep blood sugar levels controlled. Researchers are therefore recommending that most children with type 1 diabetes delay annual diabetic retinopathy screenings until age 15, or 5 years after their diabetes diagnosis, whichever occurs later.

2 Sep 2015

Researchers discover that vitamin D may play significant role in preventing AMD among women

Vitamin D has been studied extensively in relation to bone health as well as cancer. Now, a team led by a researcher at the University at Buffalo has discovered that vitamin D may play a significant role in eye health, specifically in the possible prevention of age-related macular degeneration, or AMD, among women who are more genetically prone to developing the sight-damaging disease.

1 Sep 2015

Blindness News and Research

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

New research sheds light on how retina sets its own biological rhythm using neuropsin

Researchers receive NIH grants to find genomic regions containing variants that affect disease risk

University of Alberta researchers discover diabetes 'dimmer' switch

Quethera receives seed investment funding to develop gene therapy for glaucoma

UK’s GPs, optometrists confirm link between smoking and loss of vision

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

World Scientific's latest book to be launched on Stem Cell Awareness Day

AMD Alliance hosts webinar to promote awareness and knowledge about macular disease

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Envision inaugurates 10th Annual Conference, honors outstanding achievements in low vision rehabilitation

IRIDEX launches novel intra-ocular pressure monitoring device

Kilimanjaro Project receives 2015 António Champalimaud Vision Award

New findings hold promising implications for blindness caused by limbal stem cell deficiency

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Mitochondrial Pyruvate Carrier could potentially be a new drug target to treat diabetes

Central visual field loss may delay driver's ability to detect pedestrians in timely manner

Annual diabetic retinopathy screening for children with type 1 diabetes should begin at later age, study says

Researchers discover that vitamin D may play significant role in preventing AMD among women

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News